Additional Clinical Benefit for Patient Relevant Endpoints- Investment Disincentives by AMNOG in the Example of Parkinson’s Disease
Nov 1, 2013, 00:00
10.1016/j.jval.2013.08.1852
https://www.valueinhealthjournal.com/article/S1098-3015(13)03757-1/fulltext
Title :
Additional Clinical Benefit for Patient Relevant Endpoints- Investment Disincentives by AMNOG in the Example of Parkinson’s Disease
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(13)03757-1&doi=10.1016/j.jval.2013.08.1852
First page :
A627
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
1687